- Title
- The potential impact of excluding patients with stage III epithelial ovarian cancer and no postoperative visible residual disease from the PRIMA/ENGOT-OV26/GOG-3012 trial: The AR1ZE real-world study of niraparib first-line maintenance therapy
- Creators
- Dana Chase - University of California, Los AngelesMaya Hanna - Providence CollegeJonathan Lim - Providence CollegeTirza Areli Calderón Boyle - Providence CollegeMark Guinter - Flatiron HealthMadeline Richey - Flatiron HealthKhilna Patel - Flatiron HealthJeanne Schilder - GSK, Philadelphia, PA, United StatesJean Hurteau - GSK, Waltham, MA, United StatesAmanda Golembesky - GSK, Durham, NC, United States
- Publication Details
- Gynecologic oncology, Vol.190, pp.S215-S216
- Publisher
- Elsevier Inc
- Identifiers
- 991006118538302656
- Academic Unit
- Obstetrics & Gynecology
- Language
- English
- Resource Type
- Journal article
Journal article
The potential impact of excluding patients with stage III epithelial ovarian cancer and no postoperative visible residual disease from the PRIMA/ENGOT-OV26/GOG-3012 trial: The AR1ZE real-world study of niraparib first-line maintenance therapy
Gynecologic oncology, Vol.190, pp.S215-S216
11/2024
Metrics
6 Record Views